Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 (vol 11,e006947,2025)

The following text has been modified to include lifileucel as one of the approved immunotherapy treatment options for melanoma and to update the text regarding the treatment landscape for resectable disease: 'Combination regimens including ICIs directed against programmed cell death protein 1 (PD- 1) with anticytotoxic T lymphocyte antigen- 4 (CTLA- 4) agents or, more recently, antilymphocyte- activation gene 3 (LAG- 3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long- term follow- up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence- free survival, and neoadjuvant strategies are an active area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma and bispecific T- cell engager therapy for HLA-A*02:01 genotype- positive uveal melanoma, are also available to patients.' The updated text now reads: 'Combination regimens including ICIs directed against programmed cell death protein 1 (PD- 1) with anticytotoxic T lymphocyte antigen- 4 (CTLA-4) agents or, more recently, antilymphocyte- activation gene 3 (LAG- 3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long- term follow- up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence- free survival and several are FDA- approved. Although not yet approved, neoadjuvantICIs have also shown to improve event- free survival and remains an ongoing area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma, bispecific T- cell engager therapy for HLA-A*02:01 genotype- positive uveal melanoma, and lifileucel, an autologous tumor- infiltrating lymphocyte therapy, for unresectable or metastatic melanoma are also available to patients.'